Insulin resistance in HIV protease inhibitor-associated diabetes.
about
Drug-induced diabetes mellitusOptimal timing and duration of induction therapy for HIV-1 infectionHIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitusUse Your Words Carefully: What Is a Chronic Disease?HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Glucose disorders associated with HIV and its drug therapy.Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice.HIV protease inhibitors acutely impair glucose-stimulated insulin release.Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease?Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptorsBoosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapyThe metabolic effects of lopinavir/ritonavir in HIV-negative menIndinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapyInsulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study.Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic AnalysisRisk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapyAn inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.Drug-induced endocrine and metabolic disorders.Relationships among HIV infection, metabolic risk factors, and left ventricular structure and functionIndependent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women.Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer modelsPilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications.Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAARTDiabetes and HIV: current understanding and future perspectives.Sequence-specific alterations of epitope production by HIV protease inhibitors.Insulin resistance and associated factors among HIV-infected patients in sub-Saharan Africa: a cross sectional study from Cameroon.Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues.Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.HIV infection and the pancreas: risk factors and potential management guidelines.
P2860
Q22306015-BB091BC1-E136-4A7D-90C6-6567C398AE37Q28469250-108D3C22-E892-44AA-A5B8-D25F3A811B7EQ28582686-A1030EB8-8D72-4157-961E-C1D52A33FB43Q28595560-C1A43D91-EEC9-4F3F-BAB2-DF81295DCFDBQ33729269-908E9FDF-9070-43F0-B6D1-7E3A60676458Q33941936-D64F68C6-5191-4F25-BB0E-794B4A1AF421Q33983927-CF1BE822-6ABD-4A84-9DC4-0D49A7247A4EQ34092346-5A381D0E-D5C1-4985-A309-D8966256AABEQ34191314-2DF27AE9-3EBD-493C-BDEF-B49BE4D9A2BBQ34299021-30B5E96E-C3CF-4486-A422-12475E824487Q34455624-B7FA27CD-C785-4F99-BD77-5D1FB3F88525Q34979921-0DAC9133-8DB0-49D9-BC58-B8CB6186119FQ35141509-0571C041-F830-4BB5-8512-AECB83C838A7Q35188653-96F069CD-2361-42B3-B92C-52842E14E7CCQ35194049-B6668D95-6B01-4BEE-88CC-84E3BD888920Q35194394-B4B3CB6C-C9CD-46AC-AEA8-EA408FE892CDQ35195035-7BF2A876-D99D-44AF-9D64-F5EC8515559DQ35206670-E623FCC7-3797-4227-B069-F04304A4967AQ35208120-B365D550-60DA-4C91-89B2-B1B014F6B609Q35670873-E1C7C28A-7027-48B5-8A43-0B54C68B4370Q35672526-6EB163E4-BCAF-4F4B-8421-7E7ADAF16FA4Q36011828-0D7549E3-B9C3-43DA-BAC2-5C600343B2A7Q36145648-9D637A96-319A-49B1-A710-9C025E7A3F6BQ36171039-BC253DE8-7BE0-434F-BE62-B091FF5B55D2Q36483172-C6CBE148-2A58-448E-AE5A-DCF9C288BA85Q36753691-01E705E9-DA19-4775-B1FE-1226A412954BQ37025613-1BE78919-52F3-481D-842E-4A052BD33093Q37161855-0B6A07B2-077A-4A57-B235-6E2AF787BF6EQ37162243-08DBC6A9-82DD-4B7A-B7FE-262A7F39FB44Q37250997-9083B6D1-1698-4D4B-B0B8-195EDF2FA22FQ37447923-77DF7B9E-F629-4323-9BD6-92C280CC7B22Q37602891-BCD908D4-C8FB-44F9-A96F-748878FD9227Q37604169-9D9E3417-CA68-4B2D-8BE0-DBC0E700BE47Q38085218-3AD38968-D5BA-4848-8B8E-912516479E7FQ38710071-0DB246DF-0563-43D5-B531-7A74609FDB10Q40087155-06CC6E13-5B27-4822-844B-6EBE76FEE48EQ42440254-91A08DA5-5BE5-413F-B59E-3BD778CF512FQ44081426-8FBE2E58-8530-4C15-B21A-6EB6B0A12E71Q44318804-67B4A26B-1644-428E-B45B-9E859EB304CAQ44442725-A47DF349-4F8D-466A-9BEA-6EE46E9D8661
P2860
Insulin resistance in HIV protease inhibitor-associated diabetes.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Insulin resistance in HIV protease inhibitor-associated diabetes.
@ast
Insulin resistance in HIV protease inhibitor-associated diabetes.
@en
type
label
Insulin resistance in HIV protease inhibitor-associated diabetes.
@ast
Insulin resistance in HIV protease inhibitor-associated diabetes.
@en
prefLabel
Insulin resistance in HIV protease inhibitor-associated diabetes.
@ast
Insulin resistance in HIV protease inhibitor-associated diabetes.
@en
P2093
P2860
P1476
Insulin resistance in HIV protease inhibitor-associated diabetes.
@en
P2093
K E Yarasheski
P A Halban
S Dagogo-Jack
W G Powderly
P2860
P304
P356
10.1097/00126334-199907010-00005
P407
P577
1999-07-01T00:00:00Z